Clinical Trial

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2021-11-18; most recent amendment 2026-03-20.
Trial Details
NCT Number NCT05130437
Lead Sponsor ModernaTX, Inc.
Conditions Propionic Acidemia
Enrollment 50 participants
Start Date 2021-11-09
Primary Completion 2029-12-04 (estimated)
Study Completion 2031-12-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-23